The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Preliminary Results of a Randomized Radiotherapy Dose-Escalation Study Comparing 70 Gy With 78 Gy for Prostate Cancer
Abstract
PURPOSE: To determine the effect of radiotherapy dose on prostate cancer patient outcome and biopsy positivity in a phase III trial. PATIENTS AND METHODS: A total of 305 stage T1 through T3 patients were randomized to receive 70 Gy or 78 Gy of external-beam radiotherapy between 1993 and 1998. Of these, 301 were assessable; stratification was based on pretreatment prostate-specific antigen level (PSA). Dose was prescribed to the isocenter at 2 Gy per fraction. All patients underwent planning pelvic computed tomography scan to confirm prostate position. Treatment failure was defined as an increasing PSA on three consecutive follow-up visits or the initiation of salvage treatment. Median follow-up was 40 months. RESULTS: One hundred fifty patients were randomized to the 70-Gy arm and 151 to the 78-Gy arm. The difference in freedom from biochemical and/or disease failure (FFF) rates of 69% and 79% for the 70-Gy and 78-Gy groups, respectively, at 5 years was marginally significant (log-rank P = .058). Multiple-covariate Cox proportional hazards regression showed that the study randomization was an independent correlate of FFF, along with pretreatment PSA, Gleason score, and stage. The patients who benefited most from the 8-Gy dose escalation were those with a pretreatment PSA of more than 10 ng/mL; 5-year FFF rates were 48% and 75% (P = .011) for the 70-Gy and 78-Gy arms, respectively. There was no difference between the arms (∼80% 5-year FFF) when the pretreatment PSA was ≤ 10 ng/mL. CONCLUSION: A modest dose increase of 8 Gy using conformal radiotherapy resulted in a substantial improvement in prostate cancer FFF rates for patients with a pretreatment PSA of more than 10 ng/mL. These findings document that local persistence of prostate cancer in intermediate- to high-risk patients is a major problem when doses of 70 Gy or less are used.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,234
Consensus statement: Guidelines for PSA following radiation therapy1
AMERICANSOCIETYFORTHERAPEUTICR (1997) · International Journal of Radiation OncologyBiologyPhysics · doi:10.1016/s0360-3016(97)00002-3 · Cited by 1,151
Zelefsky, M., Leibel, S., Gaudin, P., Kutcher, G., Fleshner, N., Venkatramen, E. S., Reuter, V., Fair, W., Ling, C. C., & Fuks, Z. (1998) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(98)00091-1 · Cited by 924
Hankey, B. F., Feuer, E. J., Clegg, L. X., Hayes, R. B., Legler, J. M., Prorok, P. C., Ries, L. A., Merrill, R. M., & Kaplan, R. S. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.12.1017 · Cited by 652
Fuks, Z., Leibel, S. A., Wallner, K. E., Begg, C. B., Fair, W. R., Anderson, L. L., Hilaris, B. S., & Whitmore, W. F. (1991) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(91)90668-t · Cited by 448
Shipley, W. U., Verhey, L. J., Munzenrider, J. E., Suit, H. D., Urie, M. M., McManus, P. L., Young, R. H., Shipley, J. W., Zietman, A. L., Biggs, P. J., et al. (1995) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(95)00063-5 · Cited by 407
Survivorship Analysis for Clinical Studies.
Fayers, P., Harris, E. K., & Albert, A. (1992) · Applied Statistics · doi:10.2307/2348095 · Cited by 266
Pollack, A., Zagars, G. K., Starkschall, G., Childress, C. H., Kopplin, S., Boyer, A. L., & Rosen, I. I. (1996) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(95)02103-5 · Cited by 191
Self-citationPollack, A. S., Smith, L., & von Eschenbach, A. C. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)00620-9 · Cited by 144
Self-citationHanks, G. E., Hanlon, A., Pinover, W. H., Horwitz, E. M., & Schultheiss, T. E. (1999) · PubMed · Cited by 110
Peterson, B. L., & George, S. L. (1993) · Controlled Clinical Trials · doi:10.1016/0197-2456(93)90031-8 · Cited by 99
Cited by
EAU Guidelines on Prostate Cancer
Heidenreich, A., Aus, G., Bolla, M., Joniau, S., Matveev, V. B., Schmid, H. P., & Zattoni, F. (2008) · European Urology · doi:10.1016/j.eururo.2007.09.002 · Cited by 3,136
Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial
Pollack, A., Zagars, G. K., Starkschall, G., Antolak, J. A., Lee, J. J., Huang, E., von Eschenbach, A. C., Kuban, D. A., & Rosen, I. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(02)02829-8 · Cited by 1,333
Self-citationLong-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer
Kuban, D. A., Tucker, S. L., Dong, L., Starkschall, G., Huang, E. H., Cheung, M. R., Lee, A. K., & Pollack, A. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.06.054 · Cited by 1,232
Self-citationZietman, A. L., DeSilvio, M. L., Slater, J. D., Rossi, C. J., Miller, D. W., Adams, J. A., & Shipley, W. U. (2005) · JAMA · doi:10.1001/jama.294.10.1233 · Cited by 1,224
Peeters, S. T. H., Heemsbergen, W. D., Koper, P. C. M., van Putten, W. L. J., Slot, A., Dielwart, M. F. H., Bonfrer, J. M. G., Incrocci, L., & Lebesque, J. V. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.2530 · Cited by 966
Metadata
- Authors
- Pollack, A., Zagars, G. K., Smith, L. G., Lee, J. J., von Eschenbach, A. C., Antolak, J. A., Starkschall, G., & Rosen, I.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-12-01
- Volume
- 18
- Issue
- 23
- Pages
- 3904-3911
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1868732334
- Cited by
- 521
- References
- 11
- FWCI
- 34.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.